CA2688467C - Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles - Google Patents

Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles Download PDF

Info

Publication number
CA2688467C
CA2688467C CA2688467A CA2688467A CA2688467C CA 2688467 C CA2688467 C CA 2688467C CA 2688467 A CA2688467 A CA 2688467A CA 2688467 A CA2688467 A CA 2688467A CA 2688467 C CA2688467 C CA 2688467C
Authority
CA
Canada
Prior art keywords
methoxy
amino
methoxyphenyl
compound
dichloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2688467A
Other languages
English (en)
French (fr)
Other versions
CA2688467A1 (en
Inventor
Becker Hewes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39639071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2688467(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to CA2868899A priority Critical patent/CA2868899C/en
Publication of CA2688467A1 publication Critical patent/CA2688467A1/en
Application granted granted Critical
Publication of CA2688467C publication Critical patent/CA2688467C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2688467A 2007-06-01 2008-05-30 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles Active CA2688467C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2868899A CA2868899C (en) 2007-06-01 2008-05-30 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93265007P 2007-06-01 2007-06-01
US60/932,650 2007-06-01
PCT/US2008/065215 WO2008150957A2 (en) 2007-06-01 2008-05-30 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2868899A Division CA2868899C (en) 2007-06-01 2008-05-30 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene

Publications (2)

Publication Number Publication Date
CA2688467A1 CA2688467A1 (en) 2008-12-11
CA2688467C true CA2688467C (en) 2015-05-12

Family

ID=39639071

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2688467A Active CA2688467C (en) 2007-06-01 2008-05-30 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
CA2868899A Active CA2868899C (en) 2007-06-01 2008-05-30 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene
CA2964162A Active CA2964162C (en) 2007-06-01 2008-05-30 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2868899A Active CA2868899C (en) 2007-06-01 2008-05-30 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene
CA2964162A Active CA2964162C (en) 2007-06-01 2008-05-30 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene

Country Status (23)

Country Link
US (1) US11103497B2 (cg-RX-API-DMAC7.html)
EP (4) EP2777704A3 (cg-RX-API-DMAC7.html)
JP (3) JP5888853B2 (cg-RX-API-DMAC7.html)
KR (1) KR101493543B1 (cg-RX-API-DMAC7.html)
CN (1) CN101686973B (cg-RX-API-DMAC7.html)
AU (1) AU2008260070B9 (cg-RX-API-DMAC7.html)
BR (1) BRPI0812355A2 (cg-RX-API-DMAC7.html)
CA (3) CA2688467C (cg-RX-API-DMAC7.html)
CL (1) CL2008001577A1 (cg-RX-API-DMAC7.html)
CY (2) CY1115251T1 (cg-RX-API-DMAC7.html)
DK (2) DK2478905T3 (cg-RX-API-DMAC7.html)
ES (2) ES2881391T3 (cg-RX-API-DMAC7.html)
HU (1) HUE055524T2 (cg-RX-API-DMAC7.html)
IL (1) IL202407A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009013069A (cg-RX-API-DMAC7.html)
PA (1) PA8782301A1 (cg-RX-API-DMAC7.html)
PL (2) PL3002009T3 (cg-RX-API-DMAC7.html)
PT (2) PT3002009T (cg-RX-API-DMAC7.html)
RU (1) RU2464026C2 (cg-RX-API-DMAC7.html)
SI (2) SI3002009T1 (cg-RX-API-DMAC7.html)
TW (1) TW200908982A (cg-RX-API-DMAC7.html)
WO (1) WO2008150957A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200908480B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2777704A3 (en) * 2007-06-01 2015-01-21 Wyeth LLC Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
JP6026441B2 (ja) 2011-03-04 2016-11-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited キナーゼ阻害剤としてのアミノキノリン
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
CN105143208B (zh) 2013-02-21 2017-09-26 葛兰素史密斯克莱知识产权发展有限公司 作为激酶抑制剂的喹唑啉
KR101733665B1 (ko) * 2015-05-06 2017-05-10 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 F1 또는 Rg3을 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물
JP2022544700A (ja) * 2019-08-22 2022-10-20 バイオヘイブン・セラピューティクス・リミテッド 筋萎縮性側索硬化症および関連障害の治療のためにtdp-43に結合する分子
CN115944636A (zh) * 2022-11-01 2023-04-11 华南师范大学 博舒替尼在抑制i-motif结构上的应用
EP4746884A2 (en) * 2023-07-21 2026-05-27 Icahn School of Medicine at Mount Sinai G9a/glp inhibitors and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
CA2434526C (en) * 2001-01-25 2011-11-01 Bristol Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
EP2341133A1 (en) 2001-10-05 2011-07-06 Novartis AG Mutated Abl kinase domains
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20050010780A1 (en) * 2003-07-09 2005-01-13 Kane John Richard Method and apparatus for providing access to personal information
CA2543163A1 (en) 2003-11-06 2005-05-26 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
TW200724548A (en) 2005-04-25 2007-07-01 Pfizer Antibodies to myostatin
AU2006247322A1 (en) * 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
AU2006270187A1 (en) 2005-07-15 2007-01-25 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant SRC kinase polypeptides
KR101135220B1 (ko) 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
WO2007056177A2 (en) * 2005-11-04 2007-05-18 Bristol-Myers Squibb Pharma Company T315a and f317i mutations of bcr-abl kinase domain
EP2777704A3 (en) * 2007-06-01 2015-01-21 Wyeth LLC Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles

Also Published As

Publication number Publication date
EP2478905A2 (en) 2012-07-25
HUE055524T2 (hu) 2021-11-29
RU2009144128A (ru) 2011-07-20
CY1124391T1 (el) 2022-07-22
EP3002009B1 (en) 2021-07-07
CN101686973A (zh) 2010-03-31
JP2014111629A (ja) 2014-06-19
RU2464026C2 (ru) 2012-10-20
CA2964162A1 (en) 2008-12-11
EP3002009A3 (en) 2016-07-06
AU2008260070B2 (en) 2011-08-18
DK2478905T3 (da) 2014-06-30
IL202407A0 (en) 2010-06-30
EP2777704A2 (en) 2014-09-17
PT3002009T (pt) 2021-08-02
AU2008260070A1 (en) 2008-12-11
EP2478905A3 (en) 2013-01-16
HK1142812A1 (en) 2010-12-17
CN101686973B (zh) 2013-06-19
PA8782301A1 (es) 2009-01-23
WO2008150957A3 (en) 2009-08-06
US11103497B2 (en) 2021-08-31
ZA200908480B (en) 2010-08-25
AU2008260070B9 (en) 2012-01-19
US20080318971A1 (en) 2008-12-25
JP5888853B2 (ja) 2016-03-22
TW200908982A (en) 2009-03-01
PL2478905T3 (pl) 2014-10-31
WO2008150957A2 (en) 2008-12-11
BRPI0812355A2 (pt) 2015-01-27
CA2964162C (en) 2019-12-31
CY1115251T1 (el) 2017-01-04
EP2777704A3 (en) 2015-01-21
SI2478905T1 (sl) 2014-07-31
DK3002009T3 (da) 2021-08-02
ES2881391T3 (es) 2021-11-29
JP2010529038A (ja) 2010-08-26
EP2152267A2 (en) 2010-02-17
KR101493543B1 (ko) 2015-02-13
JP2016074700A (ja) 2016-05-12
CL2008001577A1 (es) 2008-07-25
PL3002009T3 (pl) 2021-12-13
EP2478905B1 (en) 2014-05-14
CA2868899A1 (en) 2008-12-11
EP3002009A2 (en) 2016-04-06
CA2868899C (en) 2017-06-13
SI3002009T1 (sl) 2021-09-30
PT2478905E (pt) 2014-07-16
KR20100017983A (ko) 2010-02-16
CA2688467A1 (en) 2008-12-11
MX2009013069A (es) 2010-03-17
ES2477567T3 (es) 2014-07-17

Similar Documents

Publication Publication Date Title
CA2868899C (en) Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene
US7919625B2 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
JP2002538107A (ja) アレルギー障害治療用のjak−3阻害剤
CN115006397A (zh) 一种预防或治疗肿瘤疾病的药物用途
HK1142812B (en) Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
KR102798463B1 (ko) 페로켈라타아제 억제제 및 사용 방법
WO2005047259A1 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
CN104968363A (zh) Pi3k/akt抑制剂化合物与her3/egfr抑制剂化合物的组合及使用方法
WO2026086864A1 (zh) 一种kat6抑制剂的联合使用
US20080119463A1 (en) 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008060283A1 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130110

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250409

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250409

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260413

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260413